Why SELLAS Life Sciences Group, Inc.’s (SLS) Stock Is Up 5.56%
As of Wednesday, September 30, SELLAS Life Sciences Group, Inc.’s SLS share price has surged by 5.56%, which has investors questioning if this is right time to sell.Michael Rose
Stock Evaluator: SELLAS Life Sciences Group, Inc. (SLS)
SELLAS Life Sciences Group, Inc. SLS
$11.74
0.09
0.73%
October 12, 2026 11:01:11 AM
EST
Volume: 1,294,113
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK’s WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Commentary & Analysis
Why SELLAS Life Sciences Group, Inc.’s (SLS) Stock Is Down 5.39%
As of Friday, September 11, SELLAS Life Sciences Group, Inc.’s SLS share price has dipped by 5.39%, which has investors questioning if this is right time to buy.Jenna Brashear
Why SELLAS Life Sciences Group, Inc.’s (SLS) Stock Is Down 6.05%
As of Friday, August 28, SELLAS Life Sciences Group, Inc.’s SLS share price has dipped by 6.05%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why SELLAS Life Sciences Group, Inc.’s (SLS) Stock Is Up 10.56%
As of Thursday, August 27, SELLAS Life Sciences Group, Inc.’s SLS share price has surged by 10.56%, which has investors questioning if this is right time to sell.Michael Rose
Why SELLAS Life Sciences Group, Inc.’s (SLS) Stock Is Up 10.09%
As of Thursday, August 27, SELLAS Life Sciences Group, Inc.’s SLS share price has surged by 10.09%, which has investors questioning if this is right time to sell.Tudor Pop
Financial Summary
| Share Statistics | SLS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,352.7 | $242.6 | 57% |
|
| Shares Out (Mil) | 189.2 | 54.0 | 75% |
|
| Institutional Ownership | 98.9% | 93.1% | 83% |
|
| Float (Mil) | 201.1 | 41.4 | 74% |
|
| Beta | 2.49 | 0.95 | 96% |
|
| Avg Daily Volume (000s) | 4,569 | 633 | 91% |
|
| Price Change (52-week) |
503.6% | 50.0% | 100% |
|
| Growth | SLS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.5% | na |
|
| Net Income (5yr) | (9.9%) | (10.1%) | 29% |
|
| EPS (5yr) | 34.9% | 15.8% | 85 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (31.5%) | (15.7%) | 18% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 2 | |
| Current EPS | ($0.050) | ($0.200) | ($0.100) | |
| Month Ago EPS | ($0.050) | ($0.200) | ($0.100) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.055) | ($0.210) | ($0.125) | |
| Year/Year Chg | (2.0%) | (18.7%) | (116.3%) | |
| Financials | SLS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($33) | ($44) | 20% |
|
| EPS (TTM) | ($0.212) | ($1.600) | 33% |
|
| Operating Cash Flow (TTM) (Mil) | ($28) | ($34) | 13% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 12% |
|
| Enterprise Value (Q1) (Mil) | $2,239 | $177 | 51% |
|
| Valuation | SLS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 17.13 | 2.33 | 95% |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | SLS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.3% | na |
|
| Net Margin | na | (74.8%) | na |
|
| ROA | (36.5%) | (47.6%) | 15% |
|
| ROE | (39.6%) | (54.9%) | 18% |
|
| Liabilities to Assets | 5.3% | 29.3% | 2% |
|
| F-Score | 4 | 3 | 33% |
|
SELLAS Life Sciences Group, Inc. did not pass any screens on 10/9/2026.
